What is the current market price of Zenocutuzumab per box?

Zetolizumab is a bispecific antibody that targets the HER2 and HER3 pathways. It is mainly used to treat patients with NRG1 Patients with advanced or metastatic non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) with fusion genes. This is the first systemic therapeutic drug that was granted "Breakthrough Therapy", Priority Review and Orphan Drug status by the FDA at the end of 2024, and was officially approved for marketing in December of 2024.

Although zetolizumab has not yet been sold through regular domestic channels, the retail pricing in the US market can be used as a reference. Data show that its IV injection 20 mg/mL, 37.5 mL (approximately two bottles 18.75 mL) is priced at approximately 23,206.90 US dollars, which is equivalent to about 16 ten thousand yuan in RMB (estimated based on the current exchange rate). Other off-the-shelf and investigational grade low-dose products (e.g., 5 mg approximately 1,190 USD, 10 mg approx. 1,880 USD) also shows an extremely high price per milligram. It can be deduced that the usual recommended dose at one time is 750 mg The volume is about 37.5 mL The cost of the whole box is extremely high.

As of now, zetolizumab has not been approved for marketing in mainland China, nor has it been included in the national medical insurance directory. Domestic patients cannot purchase through formal channels. If obtained through overseas medical projects, the costs required include the drug itself, high international transportation fees and possible import taxes. The actual out-of-pocket expenditure is much higher than the U.S. retail price. For example, if a box of equal-dose products is imported domestically, the overall cost may exceed RMB 20 yuan. This imposes a significant financial burden on most patients.

The future price trend of zetolizumab will be affected by many factors: including market competition after it is launched in more countries, potential biosimilars (biosimilar) entering the market, and medical insurance policy negotiations. Once it officially enters the Chinese market and is included in medical insurance, its price is expected to drop significantly. At the same time, with the promotion of clinical use and supply chain optimization, production costs and channel fees may show a downward trend, which will help future pricing become more reasonable. In general, the current price of a single box of zetolizumab is extremely high, and it is only suitable for a small number of patients imported through special approval channels. Future prices can be expected, but it still takes time.

Reference materials:https://www.drugs.com/